Asset / Drug

Abemaciclib

Drug and asset intelligence for Abemaciclib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Recent signals(1)

ClinicalJune 21, 2026

Phase I/II Trial of Abemaciclib with Gemcitabine for Advanced Soft Tissue Sarcoma

A phase I/II trial is evaluating the safety and efficacy of abemaciclib combined with gemcitabine versus gemcitabine with docetaxel in patients with advanced soft tissue sarcoma.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Abemaciclib

Monitor trial results and safety data, as well as any announcements regarding further development or regulatory submissions.

June 21, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Oncology →

Oncology · Soft Tissue Sarcoma →

Soft Tissue Sarcoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.